Dihydropyridine calcium-channel blockers are also effective in lowering blood pressure in high volume states and have great potency in reducing arterial smooth muscle cell contractility in the blood vessels, which is one of the mechanisms associated with VEGF induced hypertension. The gene discussed is VEGFA; the disease is hypertensive disorder.